Focused On-demand Library for Importin subunit alpha-7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O60684

UPID:

IMA7_HUMAN

Alternative names:

Karyopherin subunit alpha-6

Alternative UPACC:

O60684; B2RDC7; D3DPP5; Q5VVU3

Background:

Importin subunit alpha-7, also known as Karyopherin subunit alpha-6, plays a crucial role in nuclear protein import. It functions as an adapter for nuclear receptor KPNB1, binding directly to substrates with NLS motifs. This protein is essential for the docking of the importin/substrate complex to the nuclear pore complex, facilitated by KPNB1's interaction with nucleoporin FxFG repeats. The complex's translocation through the pore is powered by a Ran-dependent mechanism, highlighting the protein's significance in cellular function.

Therapeutic significance:

Understanding the role of Importin subunit alpha-7 could open doors to potential therapeutic strategies. Its pivotal function in nuclear import underscores its potential as a target in diseases where this process is dysregulated.